The Fanconi anemia and BRCA networks are considered interconnected, as BRCA2 gene defects have been discovered in individuals with Fanconi anemia subtype D1. Here we show that a defect in the BRCA2-interacting protein PALB2 is associated with Fanconi anemia in an individual with a new subtype. PALB2-deficient cells showed hypersensitivity to cross-linking agents and lacked chromatin-bound BRCA2; these defects were corrected upon ectopic expression of PALB2 or by spontaneous reversion.
Subscribe to Journal
Get full journal access for 1 year
only $18.75 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Levitus, M. et al. Cell Oncol. 28, 3–29 (2006).
Taniguchi, T. & D'Andrea, A.D. Blood 107, 4223–4233 (2006).
Howlett, N.G. et al. Science 297, 606–609 (2002).
Levitus, M. et al. Nat. Genet. 37, 934–935 (2005).
Xia, B. et al. Mol. Cell 22, 719–729 (2006).
Schouten, J.P. et al. Nucleic Acids Res. 30, e57 (2002).
Batzer, M.A. & Deininger, P.L. Nat. Rev. Genet. 3, 370–379 (2002).
Waisfisz, Q. et al. Nat. Genet. 22, 379–383 (1999).
Chang, M.W. Lymphat. Res. Biol. 1, 259–265 (2003).
Mueller, B.U. & Mulliken, J.B. Semin. Perinatol. 23, 332–340 (1999).
Alter, B.P. et al. J. Med. Genet. published online 20 October 2006 (doi:10.1136/jmg.2006.043257).
Lorenzo Bermejo, J. & Hemminki, K. Ann. Oncol. 15, 1834–1841 (2004).
Friedenson, B. MedGenMed 7, 60 (2005).
We thank the family of individual EUFA1341 for contributing to this study, M. Makiya and C. de Leon Lucero for help in the collection of clinical data and J. Steltenpool and A. Oostra for expert technical assistance. The members of the Livingston laboratory are grateful to A. D'Andrea and his colleagues at the Dana Farber Cancer Institute for a number of useful discussions and for Fanconi anemia-related reagents. This study was financially supported by the Netherlands Organization for Health Research and Development (J.P.d.W. and N.A.); by grants, including a breast cancer SPORE, from the National Cancer Institute (D.M.L.); by the Breast Cancer Program of US Army Medical Research and Materiel Command (B.X.); by the Intramural Research Program of the National Institute on Aging, US National Institutes of Health (W.W.) and by the Fanconi Anemia Research Fund (H.J.)
D.M.L is a scientific consultant to and recipient of a research grant from Novartis AG. A.E. is an employee of MRC-Holland BV.
About this article
Cite this article
Xia, B., Dorsman, J., Ameziane, N. et al. Fanconi anemia is associated with a defect in the BRCA2 partner PALB2. Nat Genet 39, 159–161 (2007). https://doi.org/10.1038/ng1942
Breast Cancer Research and Treatment (2020)
Missense PALB2 germline variant disrupts nuclear localization of PALB2 in a patient with breast cancer
Familial Cancer (2020)
Recent advances of therapeutic targets based on the molecular signature in breast cancer: genetic mutations and implications for current treatment paradigms
Journal of Hematology & Oncology (2019)
Cell Reports (2019)
Nature Communications (2019)